The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
22-Jan-18
$375 million
Target:
Lonmin
Advising Lonmin PLC, a major fully integrated producer of Platinum Group Metals, on the amendment of its debt facilities to support the review and implementation of its strategic options
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
09-Nov-15
$777 million
Target:
Lonmin Plc
Advised Lonmin Plc on its c.$777mm recapitalization consisting of c.$370mm of bank facilities at the Plc and in South Africa from the Company’s ten lending banks and a fully underwritten Rights Issue of c.$407mm.
03-Mar-14
$3.6 billion
Target:
hibu plc (formerly Yell Group plc)
Advised hibu, a full service provider of digital and print marketing services for SMEs and owner of print directory brands Yellow Pages (UK), Yellowbook (US) and Paginas Amarillas (Spain), on the comprehensive restructuring of its £2.2 billion balance sheet debt
09-Nov-12
~$1.7 billion
Target:
Lonmin plc
Advised Lonmin plc, the world’s third largest primary producer of Platinum Group Metals, on a comprehensive refinancing of its balance sheet, including an underwritten ~$817mm rights issue and amendments to its existing ~$929mm debt facilities
01-Aug-12
$4.0 billion
Target:
Mediclinic International Limited
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company